A woman in her 40s was left distressed after an AI-assisted preventive health screening package costing more than ₹20,000 flagged her as being at possible risk of pancreatic cancer. However, a subsequent medical evaluation by a specialist found no evidence of cancer.
Endocrinologist Dr. Hema Venkataraman shared the case on social media, highlighting concerns about the growing use of AI-driven health screening tools without adequate clinical interpretation.
According to Dr. Venkataraman, the screening report suggested a possible pancreatic cancer risk based on a mildly elevated CA19-9 level, despite normal imaging findings. The patient reportedly became anxious after receiving the report, which presented the findings in a manner that appeared medically alarming.
Dr. Venkataraman emphasized that CA19-9 is not a reliable standalone screening test for pancreatic cancer and should not be interpreted without considering a patient's clinical history, symptoms, and other diagnostic findings.
CA19-9 is a tumor marker that may be elevated in some people with pancreatic cancer, but it can also increase in several non-cancerous conditions, including gallstones, pancreatitis, liver disease, diabetes, and benign biliary obstruction.
In addition, not all pancreatic cancers produce elevated CA19-9 levels. Because of its limited specificity and sensitivity, major cancer organizations do not recommend CA19-9 as a routine screening test for pancreatic cancer in asymptomatic individuals.
According to the American Cancer Society, CA19-9 is not used by itself to screen for or diagnose pancreatic cancer and is more commonly used to help monitor treatment response or disease progression.¹
“Don’t do tests if you don’t know what to do with the results,” she cautioned, stressing the importance of evidence-based cancer screening protocols and specialist oversight.
The endocrinologist also raised concerns about the lack of appropriate referral pathways and medical interpretation in some preventive screening packages. According to her, sophisticated presentation and premium healthcare branding can sometimes overshadow sound clinical judgment.
She noted that cancer screening requires careful test selection, specialist review, and evidence-based protocols to avoid unnecessary anxiety and confusion among patients.
Pathologist Dr. Ravi Mehrotra also weighed in on the discussion on social media, cautioning against cancer screening conducted without physician involvement. He wrote, "Fishing expeditions for cancer without a physician involved can be counterproductive and expensive, if not downright dangerous." His remarks echoed criticism of overtesting and unnecessary patient anxiety.
Major cancer organizations, including the American Cancer Society, the National Comprehensive Cancer Network (NCCN), and the American Society of Clinical Oncology (ASCO), recommend that cancer screening and diagnostic decisions be interpreted in the context of a patient's symptoms, risk factors, and overall clinical assessment.²⁻⁴
Following consultation and additional evaluation, the patient was reassured that there was no evidence of pancreatic cancer. Dr. Venkataraman stated that while more than ₹20,000 had been spent on the initial screening, the patient incurred additional expenses for further consultations and scans to confirm that the cancer warning was unfounded.
“₹20,000 spent creating anxiety, Another ₹10,000 spent proving the ₹20,000 was a mistake!,” Dr. Venkataraman wrote.
She also added, "Moral of the story: screening should start with your doctor! Not in the lab / fancy machine however exotic the interiors!"
Several social media users expressed concern about overtesting and the interpretation of screening results, while others debated whether AI tools can effectively replace clinical judgment.
American Cancer Society. “Tests for Pancreatic Cancer.” American Cancer Society. Accessed June 19, 2026. https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/how-diagnosed.html
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Plymouth Meeting, PA: NCCN, latest edition. https://www.nccn.org
American Society of Clinical Oncology. “Pancreatic Cancer: Diagnosis.” Cancer.Net. Accessed June 19, 2026. https://www.cancer.net/cancer-types/pancreatic-cancer/diagnosis
American Cancer Society. “Can Pancreatic Cancer Be Found Early?” American Cancer Society. Accessed June 19, 2026. https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/detection.html
(Rh/ARC/MSM)